This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kinders, R. J. Search for Related Content PubMed PubMed Citation Articles by Kinders, R. J.

Preclinical Modeling of a Phase 0 Clinical Trial: Qualification of a Pharmacodynamic Assay of Poly (ADP-Ribose) Polymerase in Tumor Biopsies of Mouse Xenografts

Authors' Affiliations: ¹ Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Support Directorate, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick; ² Biological Testing Branch, Developmental Therapeutics Program, National Cancer Institute, Frederick, Maryland and ³ Biometric Research Branch, ⁴ Division of Cancer Treatment and Diagnosis, and ⁵ Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland

Requests for reprints: Robert J. Kinders, Laboratory of Human Toxicology and Pharmacology, Applied/Developmental Research Support Directorate, Science Applications International Corporation-Frederick, Inc., National Cancer Institute-Frederick, P.O. Box B, Frederick, MD 21702. Phone: 301-846-6410; Fax: 301-846-6536; E-mail: kindersr{at}mail.nih.gov.

Purpose: The National Cancer Institute has completed a first-in-human clinical pharmacodynamic trial of the targeted agent ABT-888, a poly (ADP-ribose) polymerase (PARP) inhibitor, under the auspices of the U.S. Food and Drug Administration's Exploratory Investigational New Drug Application. Performance of the study design, needle biopsy procedure, and validated pharmacodynamic assay were evaluated in human tumor xenograft models.

Experimental Design: A validated ELISA was used to quantify PAR, a product of the PARP 1/2 enzyme activity. Sampling variability from tumor heterogeneity was determined by comparing PAR content in multiple tumors, and in different areas of the same tumor in a particular animal, collected under anesthesia by needle biopsy or resection before and after administration of nontoxic doses of ABT-888. The degree of PARP inhibition following single-dose treatment was evaluated in the time frame anticipated for biopsy in humans.

Results: Sampling variability around the mean (50%) for untreated and vehicle-treated animals was random and due to specimen heterogeneity. PAR levels in initial and repeat tumor biopsies, separated by 1 week, were not altered by the stress induced by daily handling of the animals. A single ABT-888 dose (3 or 12.5 mg/kg) reduced intratumor PAR levels by >95%. ABT-888 (1.56-25 mg/kg) significantly decreased PAR levels at 2 h post-dosing.

Conclusion: The detailed methodologies developed for this study facilitated the design of a phase 0, first-in-human clinical trial of ABT-888 and could serve as a model for developing proof-of-principle clinical trials of molecularly targeted anticancer agents.

This article has been cited by other articles:

				S. Kummar, R. Kinders, M. E. Gutierrez, L. Rubinstein, R. E. Parchment, L. R. Phillips, J. Ji, A. Monks, J. A. Low, A. Chen, et al. Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies J. Clin. Oncol., June 1, 2009; 27(16): 2705 - 2711. [Abstract] [Full Text] [PDF]

				M. J. Clarke, E. A. Mulligan, P. T. Grogan, A. C. Mladek, B. L. Carlson, M. A. Schroeder, N. J. Curtin, Z. Lou, P. A. Decker, W. Wu, et al. Effective sensitization of temozolomide by ABT-888 is lost with development of temozolomide resistance in glioblastoma xenograft lines Mol. Cancer Ther., February 1, 2009; 8(2): 407 - 414. [Abstract] [Full Text] [PDF]